Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3848580 | 1.00 | L3MBTL1 (0.43) | L3MBTL1MEN1KMT2ATDP1LMNA | |
| Bromide SCHEMBL3844964 | 1.00 | L3MBTL1 (0.43) | L3MBTL1MEN1KMT2ATDP1LMNA | |
| Bromide SCHEMBL3854419 | 0.88 | THRA (0.38) | L3MBTL1MEN1KMT2ALMNA | |
| Bromide SCHEMBL7054583 | 0.86 | KMT2A (0.35) | L3MBTL1MEN1KMT2ATDP1LMNA | |
| Bromide SCHEMBL5981811 | 0.81 | KMT2A (0.36) | MEN1KMT2A | |
| Bromide SCHEMBL3847620 | 0.78 | LMNA (0.45) | L3MBTL1MEN1KMT2ATDP1LMNA | |
| Bromide SCHEMBL7052826 | 0.78 | ALDH1A1 (0.33) | MEN1KMT2ALMNA | |
| Bromide SCHEMBL3845782 | 0.70 | LMNA (0.54) | L3MBTL1MEN1KMT2ALMNA | |
| Bromide SCHEMBL3846555 | 0.70 | LMNA (0.54) | L3MBTL1MEN1KMT2ALMNA | |
| Bromide SCHEMBL3846115 | 0.70 | LMNA (0.54) | L3MBTL1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1128830-B1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | SYNVISTA THERAPEUTICS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6790859-B2 | THERAPY OR REDUCING PROGRESSION OF HYPERTENSION OR DAMAGE TO A TISSUE CAUSED BY CONTACT WITH ELEVATED LEVELS OF REDUCING SUGARS IN AN ANIMAL, COMPRISING ADMINISTERING TO THE ANIMAL AN EFFECTIVE AMOUNT OF THIAZOLIUM COMPOUNDS | ALTEON INCORPORATED | 2004-09-14 | — | — | US | disclosed |
| US-20030185776-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2003-10-02 | — | — | US | disclosed |
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | SYNVISTA THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | WAGLE DILIP R (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6319934-B1 | TREATING STIFFENING OF BLOOD VASCULATURE, ATHEROSCLEROSIS, RETINOPATHY, CATARACTS, PERIPHERAL NEUROPATHY OR OSTEOARTHRITIS IN AN ANIMAL | ALTEON, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6121300-A | IN A TOPICAL COSMETIC AS SKIN ELASTICITY IMPROVER OR WRINKLE REDUCER; COMPOUNDS SUCH AS 3-(2-(3-PHENYL-5-ISOXAZOLYL)-2-OXOETHYL)-THIAZOLIUM; ADMINSISTERING TO TREAT CATARACTS, PROTEIN AGING AND DIABETES | SYNVISTA THERAPEUTICS, INC. | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185776-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, MMP1 | L3MBTL1 4494/4885MEN1 1163/4885KMT2A 2650/4885 |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | L3MBTL1 3390/4885MEN1 1999/4885KMT2A 4599/4885 |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | L3MBTL1 4287/4885MEN1 1166/4885KMT2A 2711/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | L3MBTL1 4609/4885MEN1 1815/4885KMT2A 4535/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | L3MBTL1 3653/4885MEN1 2481/4885KMT2A 4545/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | L3MBTL1 4461/4885MEN1 3331/4885KMT2A 4493/4885 |
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | AGER, OGA, PTMS | L3MBTL1 1133/4885MEN1 4169/4885KMT2A 2454/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | L3MBTL1 3021/4885MEN1 2134/4885KMT2A 4326/4885 |
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | AGER, OGA, PTMS | L3MBTL1 1247/4885MEN1 4175/4885KMT2A 2486/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | L3MBTL1 1983/4885MEN1 3327/4885KMT2A 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.